These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

875 related items for PubMed ID: 18324695

  • 1. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
    Luermans JG, Post MC, Schräder R, Sluysmans T, Vydt T, Vermeersch P, Chessa M, Onorato E, Goy JJ, Budts WI.
    Catheter Cardiovasc Interv; 2008 May 01; 71(6):822-8. PubMed ID: 18324695
    [Abstract] [Full Text] [Related]

  • 2. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
    Spies C, Timmermanns I, Reissmann U, van Essen J, Schräder R.
    Catheter Cardiovasc Interv; 2008 Feb 15; 71(3):390-5. PubMed ID: 18288745
    [Abstract] [Full Text] [Related]

  • 3. Another addition to the tool box.
    Tuzcu EM.
    Catheter Cardiovasc Interv; 2008 May 01; 71(6):829-30. PubMed ID: 18412080
    [No Abstract] [Full Text] [Related]

  • 4. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism.
    Wahl A, Kunz M, Moschovitis A, Nageh T, Schwerzmann M, Seiler C, Mattle HP, Windecker S, Meier B.
    Heart; 2008 Mar 01; 94(3):336-41. PubMed ID: 17639093
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
    Kutty S, Brown K, Asnes JD, Rhodes JF, Latson LA.
    Am J Cardiol; 2008 May 15; 101(10):1487-92. PubMed ID: 18471463
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: acute results from the FORECAST registry.
    Alameddine F, Block PC.
    Catheter Cardiovasc Interv; 2004 Aug 15; 62(4):512-6. PubMed ID: 15274163
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Paradoxical embolism through the patent foramen ovale--the elderly is where the money is.
    Meier B.
    Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):971-2. PubMed ID: 19021283
    [No Abstract] [Full Text] [Related]

  • 13. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial.
    Hong TE, Thaler D, Brorson J, Heitschmidt M, Hijazi ZM, Amplatzer PFO Investigators.
    Catheter Cardiovasc Interv; 2003 Dec 01; 60(4):524-8. PubMed ID: 14624434
    [Abstract] [Full Text] [Related]

  • 14. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism.
    Spies C, Khandelwal A, Timmemanns I, Kavinsky CJ, Schräder R, Hijazi ZM.
    Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):966-70. PubMed ID: 18942060
    [Abstract] [Full Text] [Related]

  • 15. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T, Petzsch M, Ince H, Rehders TC, Körber T, Weber F, Schneider H, Auf der Maur C, Nienaber CA.
    J Interv Cardiol; 2005 Jun 01; 18(3):173-9. PubMed ID: 15966921
    [Abstract] [Full Text] [Related]

  • 16. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism.
    Harms V, Reisman M, Fuller CJ, Spencer MP, Olsen JV, Krabill KA, Gray WA, Jesurum JT.
    Am J Cardiol; 2007 May 01; 99(9):1312-5. PubMed ID: 17478164
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW, Reeder GS, Lennon RJ, Slusser JP, Freund MA, Cabalka AK, Cetta F, Hagler DJ.
    Catheter Cardiovasc Interv; 2017 Jan 01; 89(1):124-133. PubMed ID: 27027873
    [Abstract] [Full Text] [Related]

  • 18. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
    Ussia GP, Cammalleri V, Mulè M, Scarabelli M, Barbanti M, Scardaci F, Mangiafico S, Immè S, Capodanno D, Tamburino C.
    Catheter Cardiovasc Interv; 2009 Oct 01; 74(4):607-14. PubMed ID: 19360875
    [Abstract] [Full Text] [Related]

  • 19. Exclusion of patients with arteriosclerosis reduces long-term recurrence rate of presumed arterial embolism after PFO closure.
    Dubiel M, Bruch L, Liebner M, Schmehl I, Winkelmann A, Rux S, Sonntag S, Wulff H, Grad MO, Kleber FX.
    J Interv Cardiol; 2007 Aug 01; 20(4):275-81. PubMed ID: 17680857
    [Abstract] [Full Text] [Related]

  • 20. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke.
    Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N.
    Catheter Cardiovasc Interv; 2006 Nov 01; 68(5):741-6. PubMed ID: 17039525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.